122 related articles for article (PubMed ID: 36220033)
1. [Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)].
Faingold MC; Luquez C; Oviedo A; Puchulu F; Re M
Medicina (B Aires); 2022; 82(5):752-759. PubMed ID: 36220033
[TBL] [Abstract][Full Text] [Related]
2. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Haahr H; Heise T
Clin Pharmacokinet; 2020 Feb; 59(2):155-172. PubMed ID: 31667789
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
[TBL] [Abstract][Full Text] [Related]
4. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
[TBL] [Abstract][Full Text] [Related]
5. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart.
Shiramoto M; Nishida T; Hansen AK; Haahr H
J Diabetes Investig; 2018 Mar; 9(2):303-310. PubMed ID: 28556616
[TBL] [Abstract][Full Text] [Related]
6. [Faster Insulin Aspart - a new prandial insulin analogue].
Flekač M
Vnitr Lek; 2017; 63(10):697-702. PubMed ID: 29127752
[TBL] [Abstract][Full Text] [Related]
7. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
[TBL] [Abstract][Full Text] [Related]
8. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Basu A; Pieber TR; Hansen AK; Sach-Friedl S; Erichsen L; Basu R; Haahr H
Diabetes Obes Metab; 2018 Jul; 20(7):1615-1622. PubMed ID: 29493118
[TBL] [Abstract][Full Text] [Related]
9. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
10. [Faster aspart insulin (FIASP®)].
Paquot N; Scheen AJ
Rev Med Liege; 2018 Apr; 73(4):211-215. PubMed ID: 29676875
[TBL] [Abstract][Full Text] [Related]
11. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Senior P; Hramiak I
Can J Diabetes; 2019 Oct; 43(7):515-523. PubMed ID: 30872107
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
[TBL] [Abstract][Full Text] [Related]
14. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
Heise T; Hövelmann U; Brøndsted L; Adrian CL; Nosek L; Haahr H
Diabetes Obes Metab; 2015 Jul; 17(7):682-8. PubMed ID: 25846340
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
[TBL] [Abstract][Full Text] [Related]
16. The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.
Biester T; von dem Berge T; Bendtsen LQ; Bendtsen MD; Rathor N; Danne T; Haahr H
Pediatr Diabetes; 2020 Aug; 21(5):781-790. PubMed ID: 32306477
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial.
Komatsu M; Ekelund M; Horio H; Kadowaki T
Endocr J; 2021 Apr; 68(4):429-440. PubMed ID: 33390422
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan.
Kawamura T; Kikuchi T; Horio H; Rathor N; Ekelund M
Endocr J; 2021 Apr; 68(4):409-420. PubMed ID: 33518615
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Properties of Faster-Acting Insulin Aspart.
Biester T; Kordonouri O; Danne T
Curr Diab Rep; 2017 Sep; 17(11):101. PubMed ID: 28940145
[TBL] [Abstract][Full Text] [Related]
20. Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus.
Davis A; Kuriakose J; Clements JN
Clin Pharmacokinet; 2019 Apr; 58(4):421-430. PubMed ID: 29978361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
